Gallopamil
Calcium channel blocker drug
- C08DA02 (WHO)
- (RS)-5-[2-(3,4-Dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
- 16662-47-8
Y - HCl: 16662-46-7 Y
- 1234
- 1197
N
- 39WPC8JHR8
- HCl: VT4VR32A0T Y (HCl)
- D01969 Y
- ChEMBL51149 N
- DTXSID5045172
- Interactive image
- N#CC(c1cc(OC)c(OC)c(OC)c1)(CCCN(CCc2ccc(OC)c(OC)c2)C)C(C)C
InChI
- InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3N
- Key:XQLWNAFCTODIRK-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Gallopamil (INN) is an L-type calcium channel blocker that is an analog of verapamil. It is used in the treatment of abnormal heart rhythms.[1]
References
- ^ Sewing KF, Hannemann H (1983). "Calcium channel antagonists verapamil and gallopamil are powerful inhibitors of acid secretion in isolated and enriched guinea pig parietal cells". Pharmacology. 27 (1): 9–14. doi:10.1159/000137824. PMID 6310646.
- v
- t
- e
| VGKCsTooltip Voltage-gated potassium channels |
| ||||
|---|---|---|---|---|---|
| IRKsTooltip Inwardly rectifying potassium channel |
| ||||
| KCaTooltip Calcium-activated potassium channel |
| ||||
| K2PsTooltip Tandem pore domain potassium channel |
|
| VGSCsTooltip Voltage-gated sodium channels |
| ||||
|---|---|---|---|---|---|
| ENaCTooltip Epithelial sodium channel |
| ||||
| ASICsTooltip Acid-sensing ion channel |
|
| CaCCsTooltip Calcium-activated chloride channel |
| ||||
|---|---|---|---|---|---|
| CFTRTooltip Cystic fibrosis transmembrane conductance regulator |
| ||||
| Unsorted |
|
| TRPsTooltip Transient receptor potential channels |
|
|---|---|
| LGICsTooltip Ligand gated ion channels |
|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
